Basilea lands BARDA bioterrorism contract worth up to $89m
This article was originally published in Scrip
Executive Summary
Swiss biotech Basilea Pharmaceutica snagged a contract with the US Biomedical Advanced Research and Development Authority (BARDA) worth potentially up to $89 million to develop the firm's experimental monosulfactam antibiotic BAL30072 against multidrug-resistant Gram-negative pathogens, including the bioterrorism threats melioidosis and glanders.